Register
Login

Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Maria Oliva-Hemker, CCC 2021: Treatment Updates: Where Do Immunomodulators Fit in Current Approaches to Therapy? (Part 1)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 8th 2021

It was a pleasure to talk to Maria Oliva-Hemker (Johns Hopkins University School of Medicine, Baltimore, MD, US) around her presentation on ‘Treatment Updates: Where Do Immunomodulators Fit in Current Approaches to Therapy?’ which was presented at the virtual 2021 Crohn’s & Colitis Congress.

Questions

  1. What has clinical data taught us about the role of immunomodulator monotherapy for induction and maintenance of remission in paediatric IBD therapy? (0:15)
  2. At what stage would you advise a step up to anti-TNF therapy? (4:22)
  3. When should we use immunotherapy in combination with anti-TNFs agents? (5:31)

Disclosures: Maria Oliva-Hemker has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of CCC 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup